C83.29 Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, extranodal and solid organ sites

Name of the Condition

• Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, extranodal and solid organ sites
• Also known as ICD-10 code C83.29

Summary

Mixed small and large cell (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of both small and large lymphoid cells in a diffuse pattern. It typically involves abnormal growth of B-cells or T-cells in extranodal and solid organ sites, without forming follicular structures. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific cell composition and distribution.

Causes

The exact cause of mixed small and large cell (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes or masses in extranodal or solid organ sites.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Abdominal pain or swelling (if organs like the spleen or liver are involved).

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging studies (e.g., CT, MRI, or PET scans) to identify affected sites, and tissue biopsy (e.g., excisional or core needle biopsy) to confirm the presence of mixed small and large cell lymphoma. Pathological analysis includes immunohistochemistry and flow cytometry to characterize the cell type and rule out other lymphomas. Staging may be performed to assess disease extent.

Treatment Options

Treatment depends on the stage, location, and patient factors. Options may include chemotherapy (e.g., CHOP or other regimens), immunotherapy (e.g., monoclonal antibodies), radiation therapy for localized disease, or targeted therapies. Stem cell transplantation may be considered for relapsed or high-risk cases. Multidisciplinary care with hematologists and oncologists is standard.

Prognosis and Follow-Up

Prognosis varies based on disease stage, cell type, and response to treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended, especially for patients in remission.

Complications

• Disease progression or transformation to a more aggressive subtype.
• Organ dysfunction due to tumor infiltration (e.g., liver, spleen, or gastrointestinal tract).
• Treatment-related side effects (e.g., infection risk from immunosuppression, cytopenias).
• Secondary malignancies from therapy.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known carcinogens (e.g., tobacco, excessive alcohol).
• Manage chronic infections (e.g., hepatitis, HIV) with appropriate medical care.
• Discuss family history of lymphoma with a healthcare provider for risk assessment.

When to Seek Professional Help

Seek prompt medical evaluation for persistent symptoms like unexplained weight loss, fever, night sweats, or new masses, especially if they worsen or do not resolve. Early diagnosis improves management outcomes.

Tips for Medical Coders

Use code C83.29 for mixed small and large cell (diffuse) non-Hodgkin's lymphoma when the disease is documented in extranodal or solid organ sites. Ensure documentation specifies the location (e.g., gastrointestinal tract, skin, or other non-lymph node sites) to support code assignment. Verify that the diagnosis aligns with pathological confirmation of mixed small and large cell morphology.